These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 27894611)
21. Parkinson's disease and enhanced inflammatory response. Stojkovska I; Wagner BM; Morrison BE Exp Biol Med (Maywood); 2015 Nov; 240(11):1387-95. PubMed ID: 25769314 [TBL] [Abstract][Full Text] [Related]
22. Chronic mild stress accelerates the progression of Parkinson's disease in A53T α-synuclein transgenic mice. Wu Q; Yang X; Zhang Y; Zhang L; Feng L Exp Neurol; 2016 Nov; 285(Pt A):61-71. PubMed ID: 27637804 [TBL] [Abstract][Full Text] [Related]
23. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons. Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287 [TBL] [Abstract][Full Text] [Related]
24. A brain network model explaining tremor in Parkinson's disease. Duval C; Daneault JF; Hutchison WD; Sadikot AF Neurobiol Dis; 2016 Jan; 85():49-59. PubMed ID: 26459110 [TBL] [Abstract][Full Text] [Related]
25. [Selective stimulations and lesions of the rat brain nuclei as the models for research of the human sleep pathology mechanisms]. Šaponjić J Glas Srp Akad Nauka Med; 2011; (51):85-97. PubMed ID: 22165729 [TBL] [Abstract][Full Text] [Related]
26. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Braak H; de Vos RA; Bohl J; Del Tredici K Neurosci Lett; 2006 Mar; 396(1):67-72. PubMed ID: 16330147 [TBL] [Abstract][Full Text] [Related]
27. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. Zuo L; Motherwell MS Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870 [TBL] [Abstract][Full Text] [Related]
28. Harnessing neurogenesis for the possible treatment of Parkinson's disease. Lamm O; Ganz J; Melamed E; Offen D J Comp Neurol; 2014 Aug; 522(12):2817-30. PubMed ID: 24723264 [TBL] [Abstract][Full Text] [Related]
29. Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease. Chu Y; Morfini GA; Kordower JH J Parkinsons Dis; 2016; 6(1):77-97. PubMed ID: 27003787 [TBL] [Abstract][Full Text] [Related]
31. Early Parkinson's disease symptoms in α-synuclein transgenic monkeys. Niu Y; Guo X; Chen Y; Wang CE; Gao J; Yang W; Kang Y; Si W; Wang H; Yang SH; Li S; Ji W; Li XJ Hum Mol Genet; 2015 Apr; 24(8):2308-17. PubMed ID: 25552648 [TBL] [Abstract][Full Text] [Related]
32. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration. Soria FN; Engeln M; Martinez-Vicente M; Glangetas C; López-González MJ; Dovero S; Dehay B; Normand E; Vila M; Favereaux A; Georges F; Lo Bianco C; Bezard E; Fernagut PO Hum Mol Genet; 2017 Jul; 26(14):2603-2615. PubMed ID: 28520872 [TBL] [Abstract][Full Text] [Related]
34. Why would Parkinson's disease lead to sudden changes in creativity, motivation, or style with visual art?: A review of case evidence and new neurobiological, contextual, and genetic hypotheses. Lauring JO; Ishizu T; Kutlikova HH; Dörflinger F; Haugbøl S; Leder H; Kupers R; Pelowski M Neurosci Biobehav Rev; 2019 May; 100():129-165. PubMed ID: 30629980 [TBL] [Abstract][Full Text] [Related]
35. AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo. Saal KA; Koch JC; Tatenhorst L; Szegő EM; Ribas VT; Michel U; Bähr M; Tönges L; Lingor P Neurobiol Dis; 2015 Jan; 73():150-62. PubMed ID: 25283984 [TBL] [Abstract][Full Text] [Related]
36. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model. Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432 [TBL] [Abstract][Full Text] [Related]
37. Role of α-synuclein in neurodegeneration: implications for the pathogenesis of Parkinson's disease. Yu S; Chan P Essays Biochem; 2014; 56():125-35. PubMed ID: 25131591 [TBL] [Abstract][Full Text] [Related]
38. Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease. Barrenschee M; Zorenkov D; Böttner M; Lange C; Cossais F; Scharf AB; Deuschl G; Schneider SA; Ellrichmann M; Fritscher-Ravens A; Wedel T Acta Neuropathol Commun; 2017 Jan; 5(1):1. PubMed ID: 28057070 [TBL] [Abstract][Full Text] [Related]
39. Electrophysiological assessment of nociception in patients with Parkinson's disease: A multi-methods approach. Priebe JA; Kunz M; Morcinek C; Rieckmann P; Lautenbacher S J Neurol Sci; 2016 Sep; 368():59-69. PubMed ID: 27538603 [TBL] [Abstract][Full Text] [Related]
40. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease. He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]